UroGen Pharma (URGN) Change in Receivables (2017 - 2026)

UroGen Pharma (URGN) has 9 years of Change in Receivables data on file, last reported at $22.3 million in Q1 2026.

• Quarterly Change in Receivables rose 3462.95% year-over-year to $22.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.8 million (up 552.81% YoY) and the FY2025 annual result came in at $12.8 million, up 163.02% from the prior year.
• Change in Receivables advanced to $22.3 million in Q1 2026, from $13.4 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $22.3 million in Q1 2026 to a low of -$2.7 million in Q3 2023.
• A 5-year average of $2.6 million and a median of $54000.0 in 2025 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2024 — Change in Receivables sank 509.0% — and 2026, when it soared 3462.95%.
• Tracing URGN's Change in Receivables over 5 years: stood at $3.3 million in 2022, then declined by 20.73% to $2.6 million in 2023, then sank by 196.3% to -$2.5 million in 2024, then soared by 635.16% to $13.4 million in 2025, then surged by 66.9% to $22.3 million in 2026.
• The last three Change in Receivables figures came in at $22.3 million (Q1 2026), $13.4 million (Q4 2025), and $54000.0 (Q3 2025), per Business Quant data.